Key Takeaways
- Zoetis shares plunged 20% to $88.94 Thursday, registering the S&P 500’s largest single-day decline
- First-quarter earnings of $1.53 per share fell short of the $1.60 analyst forecast; sales of $2.26B missed the $2.3B target
- Full-year EPS outlook reduced to $6.85–$7.00 from previous guidance of $7.00–$7.10
- Company leadership pointed to growing pet owner budget constraints and declining veterinary clinic traffic
- Analysts from Stifel noted actual performance is “worse than it seems” after accounting for $100M in one-time revenue gains from accounting adjustments
Shares of Zoetis (ZTS) experienced a dramatic 20% decline to $88.94 Thursday, representing the steepest loss among S&P 500 constituents during the trading session. Data from Dow Jones Market Data indicates the stock is tracking toward its weakest closing price in more than seven years, with year-to-date losses now reaching 29%.
The sharp downturn followed the animal healthcare provider’s release of first-quarter financial results that fell below expectations across key metrics.
First-quarter profit reached $1.53 per share, representing an increase from $1.48 in the prior-year period but trailing the $1.60 Street consensus. Sales advanced 3% annually to $2.26 billion, coming up short of the $2.3 billion analyst projection compiled by FactSet.
Chief Executive Kristin Peck acknowledged the quarter unfolded in a more challenging landscape than anticipated. Pet owners have become increasingly budget-conscious, resulting in reduced veterinary appointments and diminished appetite for higher-priced offerings.
Domestic revenue declined approximately 8% year-over-year to $1.1 billion. Companion animal products in the U.S. market experienced an 11% contraction, pressured by weakening demand dynamics and competitive forces.
Overseas Operations Provided Partial Offset
International sales climbed 17% year-over-year to $1.1 billion, supported by a 10% increase in companion animal product revenue. The company’s parasiticides product line served as a primary growth catalyst in these markets.
Nevertheless, the international figure incorporated approximately $100 million in revenue accelerated from a fiscal calendar alignment modification. The organization removed a one-month reporting delay for its global subsidiaries, artificially elevating Q1 international figures in a non-recurring manner.
Wall Street Analysts Highlight Hidden Weakness
Stifel analyst Jonathan Block and colleagues characterized the Q1 report as actually “worse than it seems.” After removing the $100 million realignment advantage, organic operational revenue expansion landed significantly beneath consensus projections.
Block’s research group highlighted “notable weakness” within the companion animal division as especially troubling.
In response, Zoetis slashed its 2026 annual projections. Management now anticipates adjusted EPS ranging from $6.85 to $7.00, reduced from the earlier band of $7.00 to $7.10. Analyst estimates had centered around $7.03.
Full-year revenue expectations were similarly trimmed to $9.68 billion to $9.96 billion, down from the prior forecast of $9.825 billion to $10.025 billion. The Street consensus stood at $9.89 billion.
Peck stated the organization is implementing “decisive action to sharpen commercial execution, unlock revenue, and continue to drive disciplined cost management.”
The stock’s 20% single-session plunge has pushed ZTS to price levels last observed in early 2019.
Adjusted earnings per share of $1.53 represented approximately 9% annual expansion, yet still underperformed the consensus forecast by $0.09.
Thursday’s collapse brings the full-year deterioration to 29%, marking a difficult period for an equity previously viewed as a reliable growth story within the healthcare sector.
